Form 4: Ironwood Officer Sells Shares for Tax Obligations

Ironwood Pharmaceuticals' Principal Accounting Officer, Ronald Silver, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Ronald Silver, Principal Accounting Officer of Ironwood Pharmaceuticals Inc. (IRWD), reported sales of Class A Common Stock.
• On February 23, 2026, 11,552 shares were sold at a weighted average price of $3.81 per share, with prices ranging from $3.70 to $4.05.
• On February 24, 2026, an additional 12,621 shares were sold at a weighted average price of $3.66 per share, with prices ranging from $3.60 to $3.73.
• These sales were non-discretionary 'sell to cover' transactions, executed automatically to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• Following these transactions, Ronald Silver beneficially owns 252,636 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, non-discretionary sale to cover tax obligations related to RSU vesting, rather than a discretionary trade reflecting a change in insider sentiment.

Positives

• The vesting of restricted stock units indicates ongoing compensation and retention of a key officer within the company.

Negatives

• The reported sales were non-discretionary and for tax withholding purposes, therefore not indicative of a negative outlook or lack of confidence by the reporting person.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale reported on this Form 4 represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are common practice for executives receiving equity compensation, particularly restricted stock units. These sales are typically pre-arranged and non-discretionary, distinguishing them from open market sales that might signal a change in an insider's sentiment about the company's prospects. This transaction aligns with standard executive compensation and tax planning practices within the pharmaceutical industry.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is non-discretionary and for tax purposes, not signaling a change in management confidence.
• Employees: The vesting of restricted stock units is a standard component of executive compensation, indicating continued retention and alignment of interests.

Key Dates

Keywords

Ironwood Pharmaceuticals, IRWD, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Officer Transaction